scholarly journals Plasma Leptin Levels, LEPR Q223R Polymorphism and Mammographic Breast Density: A Cross-sectional Study

2013 ◽  
Vol 28 (2) ◽  
pp. 161-167 ◽  
Author(s):  
Cher Dallal ◽  
Seymour Garte ◽  
Camille Ragin ◽  
Jiangying Chen ◽  
Stacy Lloyd ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Breast Density ◽  
Dense Breast ◽  
Mammographic Breast Density ◽  
Polymorphism Analysis ◽  
Dense Area ◽  
Cross Sectional ◽  
Plasma Leptin

Obesity is associated with breast cancer in postmenopausal women, and breast density is a marker of breast cancer risk. Leptin is produced by the adipose tissue, acts through receptors that are polymorphic in nature, and is considered a cancer growth factor. The relationship between body mass index, leptin, leptin receptors and breast density is not well studied. A cross-sectional analysis in 392 post-menopausal healthy women was conducted; participants provided permission to obtain copies of their most recent screening mammogram. Non-fasting plasma leptin levels were determined using a commercially available leptin ELISA kit. Analysis of the Q223R genotypes of the LEPR gene were performed by PCR followed by restriction fragment length polymorphism analysis using DNA extracted from buffy coat samples. A statistically significant positive relationship was observed between leptin levels and body mass index (p<0.0001); leptin was significantly positively associated with mammography total breast area and non-dense breast area (p<0.0001), while it was inversely associated with percent breast density (p<0.0001). Leptin levels varied across the LEPR Q223R polymorphism, and were higher in women homozygous for the AA variant. Percent breast density decreased across the LEPR Q223R genotype, with lower percent density in women with the AA genotype. When dense area was considered according to quartiles of leptin and stratified by LEPR Q223R, a significant inverse trend between leptin levels and dense breast area was observed only among women with the G/G genotype (p-trend<0.001). After adjustment for possible confounders, leptin levels were significantly inversely associated with percent breast density (p=0.01). A significant interaction between body mass index and leptin levels on percent breast density was observed (p=0.03). These findings suggest that the association between leptin and breast density may vary by LEPR Q223R genotype, and that body mass index and leptin may act in an interactive way in determining breast density.

scholarly journals Mammographic Breast Density and Breast Cancer Molecular Subtypes: The Kenyan-African Aspect

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Asim Jamal Shaikh ◽  
Maeve Mullooly ◽  
Shahin Sayed ◽  
Rose Ndumia ◽  
Innocent Abayo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Cross Sectional Study ◽  
Sub Saharan Africa ◽  
Analysis Of Covariance ◽  
Mammographic Breast Density ◽  
Breast Cancers ◽  
Obese Women ◽  
Dense Area ◽  
Cross Sectional

Introduction. Data examining mammographic breast density (MBD) among patients in Sub-Saharan Africa are sparse. We evaluated how MBD relates to breast cancer characteristics in Kenyan women undergoing diagnostic mammography. Methods. This cross-sectional study included women with pathologically confirmed breast cancers (n=123). Pretreatment mammograms of the unaffected breast were assessed to estimate absolute dense area (cm2), nondense area (cm2), and percent density (PD). Relationships between density measurements and clinical characteristics were evaluated using analysis of covariance. Results. Median PD and dense area were 24.9% and 85.3 cm2. Higher PD and dense area were observed in younger women (P<0.01). Higher dense and nondense areas were observed in obese women (P-trend < 0.01). Estrogen receptor (ER) positive patients (73%) had higher PD and dense area than ER-negative patients (P≤0.02). Triple negative breast cancer (TNBC) patients (17%) had lower PD and dense area (P≤0.01) compared with non-TNBCs. No associations were observed between MBD and tumor size and grade. Conclusions. Our findings show discordant relationships between MBD and molecular tumor subtypes to those previously observed in Western populations. The relatively low breast density observed at diagnosis may have important implications for cancer prevention initiatives in Kenya. Subsequent larger studies are needed to confirm these findings.

scholarly journals Is Mammographic Breast Density an Endophenotype for Breast Cancer?

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3916
Author(s):  
Ellie Darcey ◽  
Nina McCarthy ◽  
Eric K. Moses ◽  
Christobel Saunders ◽  
Gemma Cadby ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Breast Density ◽  
Disease Risk ◽  
Health Study ◽  
Mammographic Breast Density ◽  
Dense Area ◽  
Cross Sectional ◽  
Meta Analyses

Mammographic breast density (MBD) is a strong and highly heritable predictor of breast cancer risk and a biomarker for the disease. This study systematically assesses MBD as an endophenotype for breast cancer—a quantitative trait that is heritable and genetically correlated with disease risk. Using data from the family-based kConFab Study and the 1994/1995 cross-sectional Busselton Health Study, participants were divided into three status groups—cases, relatives of cases and controls. Participant’s mammograms were used to measure absolute dense area (DA) and percentage dense area (PDA). To address each endophenotype criterion, linear mixed models and heritability analysis were conducted. Both measures of MBD were significantly associated with breast cancer risk in two independent samples. These measures were also highly heritable. Meta-analyses of both studies showed that MBD measures were higher in cases compared to relatives (β = 0.48, 95% CI = 0.10, 0.86 and β = 0.41, 95% CI = 0.06, 0.78 for DA and PDA, respectively) and in relatives compared to controls (β = 0.16, 95% CI = −0.24, 0.56 and β = 0.16, 95% CI = −0.21, 0.53 for DA and PDA, respectively). This study formally demonstrates, for the first time, that MBD is an endophenotype for breast cancer.

scholarly journals Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Erica J. Lee Argov ◽  
Teofilia Acheampong ◽  
Mary Beth Terry ◽  
Carmen B. Rodriguez ◽  
Mariangela Agovino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Breast Density ◽  
Menopausal Status ◽  
Mammographic Breast Density ◽  
Age At First Birth ◽  
Dense Area ◽  
Cross Sectional ◽  
Statin Use

Abstract Background Well-tolerated and commonly used medications are increasingly assessed for reducing breast cancer risk. These include metformin and statins, both linked to reduced hormone availability and cell proliferation or growth and sometimes prescribed concurrently. We investigated independent and joint associations of these medications with mammographic breast density (MBD), a useful biomarker for the effect of chemopreventive agents on breast cancer risk. Methods Using data from a cross-sectional study of 770 women (78% Hispanic, aged 40–61 years, in a mammography cohort with high cardiometabolic burden), we examined the association of self-reported “ever” use of statins and metformin with MBD measured via clinical Breast Imaging Reporting and Data System (BI-RADS) density classifications (relative risk regression) and continuous semi-automated percent and size of dense area (Cumulus) (linear regression), adjusted for age, body mass index, education, race, menopausal status, age at first birth, and insulin use. Results We observed high statin (27%), metformin (13%), and combination (9%) use, and most participants were overweight/obese (83%) and parous (87%). Statin use was associated with a lower likelihood of high density BI-RADS (RR = 0.60, 95% CI = 0.45 to 0.80), percent dense area (PD) (β = − 6.56, 95% CI = − 9.05 to − 4.06), and dense area (DA) (β = − 9.05, 95% CI = − 14.89 to − 3.22). Metformin use was associated with lower PD and higher non-dense area (NDA), but associations were attenuated by co-medication with statins. Compared to non-use of either medication, statin use alone or with metformin were associated with lower PD and DA (e.g., β = − 6.86, 95% CI: − 9.67, − 4.05 and β = − 7.07, 95% CI: − 10.97, − 3.17, respectively, for PD) and higher NDA (β = 25.05, 95% CI: 14.06, 36.03; β = 29.76, 95% CI: 14.55, 44.96, respectively). Conclusions Statin use was consistently associated with lower MBD, measured both through clinical radiologist assessment and continuous relative and absolute measures, including dense area. Metformin use was associated with lower PD and higher NDA, but this may be driven by co-medication with statins. These results support that statins may lower MBD but need confirmation with prospective and clinical data to distinguish the results of medication use from that of disease.

scholarly journals The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3245
Author(s):  
Emma C. Atakpa ◽  
Adam R. Brentnall ◽  
Susan Astley ◽  
Jack Cuzick ◽  
D. Gareth Evans ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Weight Loss ◽  
Body Mass ◽  
Breast Density ◽  
Small Sample ◽  
Weight Loss Intervention ◽  
Short Term ◽  
Dense Area ◽  
Short Term Change ◽  
Term Change

We evaluated the association between short-term change in body mass index (BMI) and breast density during a 1 year weight-loss intervention (Manchester, UK). We included 65 premenopausal women (35–45 years, ≥7 kg adult weight gain, family history of breast cancer). BMI and breast density (semi-automated area-based, automated volume-based) were measured at baseline, 1 year, and 2 years after study entry (1 year post intervention). Cross-sectional (between-women) and short-term change (within-women) associations between BMI and breast density were measured using repeated-measures correlation coefficients and multivariable linear mixed models. BMI was positively correlated with dense volume between-women (r = 0.41, 95%CI: 0.17, 0.61), but less so within-women (r = 0.08, 95%CI: −0.16, 0.28). There was little association with dense area (between-women r = −0.12, 95%CI: −0.38, 0.16; within-women r = 0.01, 95%CI: −0.24, 0.25). BMI and breast fat were positively correlated (volume: between r = 0.77, 95%CI: 0.69, 0.84, within r = 0.58, 95%CI: 0.36, 0.75; area: between r = 0.74, 95%CI: 0.63, 0.82, within r = 0.45, 95%CI: 0.23, 0.63). Multivariable models reported similar associations. Exploratory analysis suggested associations between BMI gain from 20 years and density measures (standard deviation change per +5 kg/m2 BMI: dense area: +0.61 (95%CI: 0.12, 1.09); fat volume: −0.31 (95%CI: −0.62, 0.00)). Short-term BMI change is likely to be positively associated with breast fat, but we found little association with dense tissue, although power was limited by small sample size.

scholarly journals Tumour Size at Detection According to Different Measures of Mammographic Breast Density

2009 ◽  
Vol 16 (3) ◽  
pp. 140-146 ◽  
Author(s):  
Carolyn Nickson ◽  
Anne M Kavanagh
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Tumour Size ◽  
Mammographic Screening ◽  
Cancer Prognosis ◽  
Mammographic Breast Density ◽  
Interval Cancers ◽  
Dense Area ◽  
Screening Strategies ◽  
Continuous Measures

Objectives Breast cancer prognosis is better for smaller tumours. Women with high breast density are at higher risk of breast cancer and have larger screen-detected and interval cancers in mammographic screening programmes. We assess which continuous measures of breast density are the strongest predictors of breast tumour size at detection and therefore the best measures to identify women who might benefit from more intensive mammographic screening or alternative screening strategies. Setting and methods We compared the association between breast density and tumour size for 1007 screen-detected and 341 interval cancers diagnosed in an Australian mammographic screening programme between 1994 and 1996, for three semi-automated continuous measures of breast density: per cent density, dense area and dense area adjusted for non-dense area. Results After adjustment for age, hormone therapy use, family history of breast cancer and mode of detection (screen-detected or interval cancers), all measures of breast density shared a similar positive and significant association with tumour size. For example, tumours increased in size with dense area from an estimated mean 2.2 mm larger in the second quintile (β = 2.2; 95% Cl 0.4–3.9, P < 0.001) to mean 6.6 mm larger in the highest decile of dense area (β = 6.6; 95% Cl 4.4–8.9, P < 0.001), when compared with first quintile of breast density. Conclusions Of the breast density measures assessed, either dense area or per cent density are suitable measures for identifying women who might benefit from more intensive mammographic screening or alternative screening strategies.

scholarly journals Breast Density, Body Mass Index, and Risk of Tumor Marker-Defined Subtypes of Breast Cancer

2012 ◽  
Vol 22 (5) ◽  
pp. 340-348 ◽  
Author(s):  
Amanda I. Phipps ◽  
Diana S.M. Buist ◽  
Kathleen E. Malone ◽  
William E. Barlow ◽  
Peggy L. Porter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Tumor Marker ◽  
Body Mass ◽  
Breast Density

scholarly journals Benign breast disease and changes in mammographic breast density

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Laura L. Reimers ◽  
Mandy Goldberg ◽  
Parisa Tehranifar ◽  
Karin B. Michels ◽  
Barbara A. Cohn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Mammographic Breast Density ◽  
Computer Assisted ◽  
First Birth ◽  
Dense Area ◽  
Nulliparous Women ◽  
Using Data

Abstract Background Mammographic breast density (MBD) and benign breast disease (BBD) are two of the strongest risk factors for breast cancer. Understanding trends in MBD by age and parity in women with BBD is essential to the clinical management and prevention of breast cancer. Methods Using data from the Early Determinants of Mammographic Density (EDMD) study, a prospective follow-up study of women born in 1959–1967, we evaluated MBD in 676 women. We used linear regression with generalized estimating equations to examine associations between self-reported BBD and MBD (percent density, dense area, and non-dense area), assessed through a computer-assisted method. Results A prior BBD diagnosis (median age at diagnosis 32 years) was reported by 18% of our cohort. The median time from BBD diagnosis to first available study mammogram was 9.4 years (range 1.1–27.6 years). Women with BBD had a 3.44% higher percent MBD (standard error (SE) = 1.56, p-value = 0.03) on their first available mammogram than women without BBD. Compared with parous women without BBD, nulliparous women with BBD and women with a BBD diagnosis prior to first birth had 7–8% higher percent MBD (β = 7.25, SE = 2.43, p-value< 0.01 and β = 7.84, SE = 2.98, p-value = 0.01, respectively), while there was no difference in MBD in women with a BBD diagnosis after the first birth (β = −0.22, SE = 2.40, p-value = 0.93). Conclusion Women with self-reported BBD had higher mammographic breast density than women without BBD; the association was limited to women with BBD diagnosed before their first birth.

Sign in / Sign up

Export Citation Format

Share Document